Hypothalamic hormones treatment

The effects of treatment with selegiline, an MAO-B inhibitor, on plasma levels of insulin-like growth factor I (IGF-I) (as indicator of GH secretion), levels of monoamines and their metabolites, and the activity and content of tyrosine hydroxylase — the rate-limiting enzyme in the biosynthesis of catecholamines — in the hypothalamus and hypophysis of old animals have been studied. It is believed that the antiaging effects of selegiline are due to restoration of hypothalamic hormones. 

In the context of safety pharmacology, measurement of hypothalamic hormone concentrations is performed in the context of repeated dose treatment, to assess changes after a several days period of biological adaptation. These measurements can be added to any of the conventional subacute toxicology protocols. 

Hypoglycemia drug-induced Hypothalamic hormones Immunization agents used in Immunosuppressive medications In vitro fertilization drugs for Insomnia treatment with benzodiazepines Insulin preparations Iodine-containing products Ischemic stroke treatment of Laxatives... 

Hypothalamus and Disease. Just as diseases have been described for an excess or deficiency of almost every pituitary hormone, it can be predicted that some cases of these diseases may be due to an excess or deficiency of a hypothalamic hormone. It is not difficult to conceive possible roles of hypothalamic hormones in the diagnosis and treatment of disease. 

The response of prolactin (PRL) to the hypothalamic TSH-releasing hormone (TRH) and to insulin hypoglycemia is reduced in long-term Li+-treated patients, as is the response of growth hormone to insulin hypoglycemia however the concentration of growth hormone is also reported to be elevated during Li+ treatment [170]. 

Nemeroff CB, Bissette G, Martin JB, et al Effect of chronic treatment with thyrotropin-releasing hormone (TRH) or an analog of TRH (hnear-beta-alanine TRH) on the hypothalamic-pituitary-thyroid axis. Neuroendocrinology 30 193-199, 1980... 

---